Drug Guidance for Subsidy 01/06/2023 Botulinum toxin A for the management of focal spasticity of the lower limbs associated with stroke in adults The Ministry of Health’s Drug Advisory Committee has recommended: Clostridium botulinum toxin... See all × 01/06/2023 Botulinum toxin A for the management of focal spasticity of the lower limbs associated with stroke in adults The Ministry of Health’s Drug Advisory Committee has recommended: Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 units and 100 units injection vials for the management of focal spasticity of the lower limbs associated with stroke in adults who: have a score of 3 or more on the Modified Ashworth Scale at the target muscle intended for botulinum toxin A treatment; do not have the affected joint permanently fixed in position due to fibrotic shortening of the target muscle; and are concurrently receiving physiotherapy. Funding status RClostridium botulinum toxin type A neurotoxin complex (Botox) 50 units and 100 units injection vials are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 August 2023. RBotulinum toxin A must be administered by either a neurologist trained in movement disorder or a rehabilitation physician who has undergone training to administer botulinum toxin A. NRMAF assistance does not apply to Botox 200 units injection vial or other brands of botulinum toxin A.
INTRAMUSCULAR Select a brand starting with the letter: N NABOTA POWDER FOR SOLUTION FOR INJECTION 100 UNITS/VIAL [SIN16680P]